ArticleInfection prevention in practice2026
Impact of healthcare-associated respiratory virus infections in children.
Article in Infection prevention in practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Respiratory viruses can spread within healthcare facilities despite stringent infection prevention measures. Although healthcare-associated respiratory virus infections (HARVIs) pose a significant risk to children, paediatric HARVIs are understudied. This study aimed to evaluate the clinical characteristics of HARVIs and their impact on clinical management. Methods: This retrospective study enrolled paediatric inpatients aged ≤18 years who were hospitalized at Tokyo Metropolitan Children's Medical Center between April 2020 and March 2024. HARVIs were defined based on clinical symptoms and multiplex polymerase chain reaction (FilmArray Respiratory Panel 2.1, BioFire) tested positive for viruses beyond the incubation period following hospitalization. The primary outcome was the 30-day mortality rate. The secondary outcomes included paediatric intensive care unit (PICU) admission, escalation of respiratory support, and the postponement of discharge, planned surgery, or chemotherapy. Results: Among 277 patients, male patients comprised 31% and the median age was 31 months (interquartile range: 12-77). The most common respiratory viruses detected were the rhinovirus-enterovirus (49%), parainfluenza virus type 3 (17%), severe acute respiratory syndrome coronavirus-2 (10%), and coronaviruses HKU1, NL63, 229E, and OC43 (9%). The 30-day mortality rate was 1%. The PICU admission rate was 2%. The rate of respiratory support escalation was 17%. Postponement of discharge occurred in 8%, and surgery in 3% of the cohort. There was no postponement of chemotherapy. Conclusion: HARVIs can lead to mortality and delays in treatment of underlying conditions and postponed discharge in a paediatric hospital, underscoring the importance of implementing infection control measures for prevention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.